Actinogen Releases Phase II Interim Result and Receives US Cornerstone Investment
Actinogen Medical Ltd (ACW AU) announced the results of the Interim Analysis of its Phase II XanADu trial that is conducted independently by the...
105 Views
New FDA Draft Rules Ease Approval for Alzheimer's Drugs
This short insight was written to demonstrate the importance of using biomarkers in clinical trials for Alzheimer's Disease (AD), and is intended...
113 Views
Will Actinogen Ace Alzheimer's?
Alzheimer’s disease is an incurable neurodegenerative disorder that robs the affected individuals of memory, self-care and quality of life,...
204 Views